LKFT Lakefront Biotherapeutics - American Depositary Shares
Lakefront Biotherapeutics - American Depositary Shares के बारे में विकिपीडिया से कंपनी का अवलोकन
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
और पढ़ें
Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
History
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.
In June 2022, the business announced it would acquire CellPoint for €125 million, with milestones of up to €100 million and AboundBio for $14million.
Effective April 1, 2022 Paul Stoffels replaced cofounder and CEO of 20 years Onno van de Stolpe.
In April 2026 the company was renamed to Lakefront Biotherapeutics.
Company
A German company, Galapagos Biopharma Germany GmbH, was established in 2019 and is headquartered in Munich, Germany. In December 2021, the company established an Austrian subsidiary, Galapagos Biopharma Austria GmbH, headquartered in Vienna, Austria.
Drugs
Filgotinib (GLPG0634) a selective inhibitor of JAK1 (Janus kinase 1) being developed for the treatment of rheumatoid arthritis and potentially Crohn's disease.
GLPG1205: a first-in-class GPR84-inhibitor currently under research for the treatment of inflammatory bowel disease.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
इस टिकर के लिए अभी तक कोई फंडामेंटल डेटा नहीं है।
कार्यकर्ता और 5%+ मालिक 3 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P. ×4 फाइलिंग | 28 जुलाई 2025 | 13.22% | संशोधन | — | SEC |
| TANG CAPITAL MANAGEMENT, LLC, KEVIN TANG, TANG CAPITAL PARTNERS, LP, TANG CAPITAL PARTNERS INTERNATIONAL, LP, TANG CAPITAL PARTNERS III, INC, TANG CAPITAL PARTNERS IV, INC, CONCENTRA BIOSCIENCES, LLC | 14 फ़रवरी 2025 | 7.50% | प्रारंभिक फाइलिंग | — | SEC |
| Van Herk Investments B.V., Van Herk Investments THI B.V., Van Herk Private Equity Investments B.V., Stichting Administratiekantoor Penulata, Van Herk Management Services B.V., Onroerend Goed Beheer – en Beleggingsmaatschappij A. van Herk B.V., A. van Herk Holding B.V., Stichting Administratiekantoor Abchrys, Adrianus van Herk | 2 नवमबर 2021 | — | प्रारंभिक फाइलिंग | बोर्ड अभियान | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 18 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| EWK · iShares, Inc. | 0.58% | 37133 SH | 8 अगस्त 2026 | दैनिक |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.47% | 3949 SH | 8 अगस्त 2026 | दैनिक |
| IBB · iShares Trust | 0.08% | 305498 SH | 8 अगस्त 2026 | दैनिक |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.07% | 9655 SH | 8 अगस्त 2026 | दैनिक |
| IEUS · iShares Trust | 0.05% | 3396 SH | 8 अगस्त 2026 | दैनिक |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.04% | 188173 SH | 8 अगस्त 2026 | दैनिक |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.03% | 815 SH | 8 अगस्त 2026 | दैनिक |
| SCZ · iShares Trust | 0.02% | 113209 SH | 8 अगस्त 2026 | दैनिक |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 119870 SH | 8 अगस्त 2026 | दैनिक |
| WSML · iShares Trust | 0.01% | 2543 SH | 8 अगस्त 2026 | दैनिक |
| IEUR · iShares Trust | 0.01% | 27247 SH | 8 अगस्त 2026 | दैनिक |
| IEFA · iShares Trust | 0.00% | 320356 SH | 8 अगस्त 2026 | दैनिक |
| IDEV · iShares Trust | 0.00% | 40908 SH | 8 अगस्त 2026 | दैनिक |
| IXUS · iShares Trust | 0.00% | 62087 SH | 8 अगस्त 2026 | दैनिक |
| VXUS · VANGUARD STAR FUNDS | 0.00% | 717158 SH | 8 अगस्त 2026 | दैनिक |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 36160 SH | 8 अगस्त 2026 | दैनिक |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0.00% | 483750 SH | 8 अगस्त 2026 | दैनिक |
| VSGX · VANGUARD WORLD FUND | 0.00% | 9595 SH | 8 अगस्त 2026 | दैनिक |